John H. Ward, MD
Published: Friday, Mar 22, 2019
John H. Ward, MD, professor of Medicine, Huntsman Cancer Institute, University of Utah, discusses his preferences in multilane testing for patients with hormone receptor (HR)–positive, node-negative breast cancer. For patients with HR-positive, node-negative breast cancer who would be considered for chemotherapy, the current recommendation is the 21-gene recurrence score as it is believed to be predictive of chemotherapy benefit. However, there are a couple of caveats, Ward explains. First, if a patient has already been tested with other assays, it is unnecessary to repeat testing with the 21-gene recurrence score.
Read the full article here: